Vitality Biopharma Sponsors Clinical Research Forum on Ending Opioid Epidemic

Lack of effective response drives Los Angeles meeting to discuss immediate reduction of opiate painkillers LOS ANGELES, June 05, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids as an alternative to opiate abuse, today announced its sponsorship and...

Vitality Biopharma to Present at the 8th Annual LD Micro Invitational

LOS ANGELES, May 30, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Wednesday, June 6th at 11...

Vitality Biopharma Discovers and Patents Use of Cannabinoids for C.diff-Associated Diarrhea and Colitis

Vitality’s GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections LOS ANGELES, CA – (May 10, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...

Vitality Biopharma Launches Canadian Subsidiary Focused on Cannabinoid Genetics R&D

Wholly-owned subsidiary to enable access to best available cannabinoid compounds in a federally-compliant manner and facilitate key collaborative research programs LOS ANGELES, CA – (April 5, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Files Intellectual Property in All Major Pharmaceutical Markets Worldwide

THC prodrugs including VBX-100 designed to deliver cannabinoids for targeted therapeutic effects without psychoactivity LOS ANGELES, CA – (March 28, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...

2018 Letter to Shareholders

To the Shareholders of Vitality Biopharma, Inc., I wrote to you less than two years ago describing our discovery that a Stevia plant enzyme could be used to create a new class of cannabinoid compounds.  We quickly recognized the value, seeing that these novel molecules, known as cannabosides, might enable targeted delivery and provide therapeutic...

Vitality Biopharma CEO Robert Brooke Provides Shareholder Letter

LOS ANGELES, March 19, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise of a letter issued to Company shareholders.  “As we’re poised to enter a...

Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100

Treatment of pediatric ulcerative colitis will be pursued using targeted cannabinoid therapy that avoids drug psychoactivity LOS ANGELES, CA – ( January 17, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of...

Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC

THC safety record and prior FDA approval propels Vitality’s prodrug as targeted treatment for pediatric IBD without drug psychoactivity LOS ANGELES, CA – (January 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...

Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

R&D operations in California registered with DEA to enable production of new class of cannabinoid pharmaceuticals LOS ANGELES, CA – ( November 1, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the...